* If you want to update the article please login/register
Anthrothrozole is most commonly used for the treatment of oestrogen receptor-positive breast cancer, but it can also raise thromboembolic risk. Under Anastrozole therapy, we investigated the connection between hypercoagulation and ERu03b1 and ERu03b2 expression in breast cancer cell lines. In Model 1, MCF-7 or T47D cancer cells were treated with Anastrozole and then exposed to whole blood and platelet-rich plasma, establishing platelet involvement in the tumour bed. In Model 2, blood components were treated with Anastrozole and then exposed to cancer cells, thereby inferring circulatory effects in the vaini. Conclusion These findings provide basic science evidence demonstrating that the anastrozole treatment's hypercoagulation outcomes may be related to the tumour subphenotype. During tumor progression, clinical trials are required to determine whether measuring hypercoagulatory parameters could be useful in describing subphenotypic changes or metastatic risk.
Source link: https://doi.org/10.1007/s11239-022-02690-w
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions